A Novel Dual URAT1/GLUT9 Inhibitor Reduces Hyperuricemia by Enhancing Uric Acid Excretion and Attenuating Renal Fibrosis
<b>Background</b>: Hyperuricemia (HUA) is a metabolic disorder that severely threatens human health. Chronic uric acid (UA) overload promotes the progression of tubulointerstitial fibrosis (TIF), leading to impaired UA excretion. Our previous studies identified HIPK2 inhibitor XRF-1021, which exhibi...
שמור ב:
| Principais autores: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI AG
2026-03-01
|
| סדרה: | Pharmaceuticals |
| נושאים: | |
| גישה מקוונת: | https://www.mdpi.com/1424-8247/19/3/490 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
